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Abstract-The antitumor and radiosensitizing properties of 5-bromo-2’-deoxyuridine (BUdR) appear 
to be due, in part, to its incorporation into cellular DNA. To optimize conditions for incorporation of 
5-bromo-2’-deoxyuridine-S-monophosphate (BrdUMP) into DNA, we investigated the metabolism of 
BUdR to its DNA precursor form, the 5’-triphosphate BrdUTP, in the U251 human glioblastoma cell 
line. The results demonstrated that BrdUTP accumulated rapidly in this cell line, achieving steady- 
state values within 2 hr of drug addition. The level of BrdUTP accumulation was proportional to the 
amount of exogenous BUdR up to a concentration of lOOpM, without apparent saturation. Exposure 
of glioblastoma cells to BUdR was associated with substantial selective decreases in both the cellular 
dCTP and ‘ITP pools, the extent of which was dependent on the exogenous BUdR concentration. In 
the absence of exogenous BUdR, BrdUTP was eliminated rapidly from cells with an initial half-life of 
approximately 15 min. As the cellular BrdUTP level declined, the dCTP and lTP levels increased to 
control values. Incorporation of BrdUMP into DNA appeared linear with time as long as the cellular 
BrdUTP level remained constant. This incorporation was not enhanced by the addition of 5-fluoro-2’- 
deoxyuridine (FUdR), a potent inhibitor of thymidylate synthetase, which at a concentration of 10 nM 
had no effect on ‘ITP pools in this cell line. Thus, the decrease in cellular TTF’ pools mediated by 
BrdUTP allows the halogenated pyrimidine to enhance its own incorporation into DNA. 
5-Bromo-2’-deoxyuridine (BUdRB) is a thymidine 
analog which is readily incorporated into the DNA 
of cells, bacteria and viruses as the 5’-monophosphate 
derivative (BrdUMP) [l, 21. DNA incorporation of 
this fraudulent nucleotide is associated with diverse 
biologic activities, including antitumor and antiviral 
properties, mutagenic effects and the ability to 
increase the sensitivity of cells to radiation damage 
[l-3]. The radiosensitization effect has been exploited 
clinically by administering BUdR in conjunction 
with radiation therapy to patients with malignancies 
[4]. Glioblastomas are well-suited to treatment with 
BUdR since the rapidly dividing tumor cells should 
readily incorporate the halogenated analog whereas 
the slower dividing normal brain cells would be less 
vulnerable to the toxic effects of this agent. Initial 
attempts to administer BUdR during a prolonged 
infusion to patients were hampered by vascular and 
infectious complications, and myelosuppression 
limited the amount of BUdR that could be 
administered [5,6]. The use of an implantable 
infusion pump to administer BUdR intraarterially has 
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eliminated the vascular and infectious complications 
associated with prolonged intravenous infusion of 
this drug [7,8]. Furthermore, the development of a 
rapid and sensitive assay system has permitted 
adjustment of the drug dose to maintain plasma 
concentrations of BUdR which are therapeutic but 
not myelosuppressive [8,9]. Preliminary clinical 
results with the combination of BUdR and radiation 
therapy are encouraging [8, lo]. 
Since BUdR must be incorporated into cellular 
DNA in order to act as a radiosensitizer, recent 
reports have examined the relationship between 
BUdR concentration and incorporation of its S- 
monophosphate into glioblastoma DNA both in 
vitro and in vivo [8,11]. The in vitro studies have 
demonstrated that the incorporation of BrdUMP 
into cellular DNA can vary significantly between 
cultured cell lines. However, the reason for this 
variation has not been elucidated. To be incorporated 
into DNA, BUdR must be metabolized intracellu- 
larly to 5-bromo-2’-deoxyuridine-5’-triphosphate 
(BrdUTP), the immediate DNA precursor. There 
are three distinct kinases responsible for this 
phosphorylation [2,12], and in addition BUdR and 
its phosphorylated metabolites can be degraded by 
other enzymes. Heterogeneity between cell lines at 
any one of these metabolic steps can lead to variable 
BrdUTP levels, resulting in differential DNA 
incorporation of this analog. Alternatively, the 
relative concentration of the competing endogenous 
TI’P pool may contribute to the heterogeneity of 
BrdUMP incorporation between cell lines. Despite 
the fact that the extent of BrdUMP incorporation is 
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dependent on the ability of the cell to accumulate 
BrdUTP, the rate and extent of accumulation of this 
metabolite have not been well studied. Evaluation 
of the cellular metabolism of BUdR may identify 
cell-specific differences which result in variable DNA 
incorporation of this analog and, furthermore, such 
studies may suggest new methods for increasing the 
amount of BrdUMP incorporated into DNA to 
produce greater cytotoxicity and radiosensitization. 
Thus, the data presented here describe the 
metabolism of BUdR in glioblastoma cells in culture. 
We also report the effects of S-fluoro-2’-deoxyuridine 
(FUdR), a potent inhibitor of thymidylate synthetase, 
on this metabolism. A preliminary account of these 
studies has been presented [13]. 
MATERIALS AND METHODS 
Chemicals. RPM1 1640 cell culture medium and 
horse serum were obtained from GIBCO BRL 
(Grand Island, NY). Bovine calf serum was 
purchased from Hyclone (Logan, UT). Nucleosides 
and nucleotide standards were obtained from the 
Sigma Chemical Co. (St. Louis, MO). Ammonium 
phosphate buffer was purchased from J. T. Baker 
Inc. (Phillipsburg, NJ). All other chemicals were 
reagent grade. 
Cells. U251 glioblastoma cells were a gift from 
Dr. Dare11 Bigner, Duke University Medical Center 
[ 141. The cells were maintained as monolayer cultures 
in RPM1 1640 medium supplemented with 10% 
bovine calf serum. It was determined that less than 
0.1 ,uM thymidine was present in the serum. Cells 
used in the experiments described here were passaged 
at least 3 days prior to the beginning of the study to 
ensure that the population was in exponential growth 
at the time of drug addition. 
To harvest the cells for nucleotide analysis, 
medium from the cultures was poured off rapidly 
and the plate was washed once with phosphate- 
buffered saline (PBS). Trypsin was added (0.25%) 
to detach the cells from the plate, at which point 
ice-cold PBS with 10% horse serum was added 
rapidly to stop the trypsinization process. An aliquot 
of the well-dispersed cell suspension was removed 
for estimation of cell number using an electronic 
particle counter (Coulter Electronics, Hialeah, FL), 
and the remainder was centrifuged at -4”. The cell 
pellet was then extracted with 0.4 N perchloric acid 
and neutralized with potassium hydroxide to isolate 
the acid-soluble nucleotides. The cell extract was 
stored at -20” until analysis. 
Nucleotide analysis. For analysis of cellular 
deoxyribonucleotides, the cell extract was first 
separated on a boronate affinity column to 
remove the majority of the ribonucleotides.* 
Deoxyribonucleotides were then analyzed using a 
Waters high pressure liquid chromatograph equipped 
with a U6K injector, two model 501 pumps and a 
model 490 four-channel absorbance detector. The 
system was controlled by means of Maxima 820 
software operated on a NEC Powermate 2 computer. 
The deoxyribonucleotides from the extract were 
loaded onto a strong anion exchange column 
* Manuscript in preparation. 
(Whatman, NJ) and eluted with a linear gradient of 
ammonium phosphate buffer ranging in con- 
centration from 0.15 to 0.6 M. The pH of the buffer 
was varied from 3.5 to 4.1. Nucleotides were 
identified based on their UV absorbance at 254,281 
and292 nmandcomigrationwithauthenticstandards. 
Nucleotides in cell extracts were quantitated by 
comparison of their peak areas with that of a known 
amount of the appropriate standard. 
Incorporation of BrdUMP into DNA. Cells were 
incubated with BUdR and trypsinized rapidly as 
described above. Between 2 x lo6 and 5 x lo6 cells 
were aliquotted routinely for estimation of BrdUMP 
incorporation and processed by a previously reported 
procedure [15,16]. Briefly, cells were lysed and 
treated with proteinase K. DNA was then isolated 
by phenyl/chloroform-isoamyl alcohol extraction 
followed by ethanol precipitation. The DNA was 
hydrolyzed to individual bases by treatment with 
DNAse I, snake venom phosphodiesterase, alkaline 
phosphatase and thymidine phosphorylase. The 
bases were extracted into ethyl acetate, derivatized 
with bis-trimethylsilyl trifluoroacetamide. Resulting 
products were then detected and quantitated using 
a Hewlett-Packard 5987A gas chromatograph/mass 
spectrometer in the selected ion monitoring mode. 
Analysis of BUdR in the cell medium. Immediately 
prior to harvesting cells exposed to BUdR, an aliquot 
of the cell medium was removed and frozen at -20” 
for quantitation of the amount of BUdR remaining 
at that time. Thawed medium samples were diluted 
and then analyzed without further processing for 
their BUdR content by a standard HPLC procedure 
[91. 
RESULTS 
Accumulation of BrdlJTP. The time- and 
concentration-dependence of BrdUTP accumulation 
was assessed in U251 glioblastoma cells. Initial 
studies demonstrated that, with BUdR con- 
centrations ranging from 2 to 20pM, BrdUTP 
accumulated rapidly, achieving steady-state values 
within 1 hr which were maintained for at least 8 hr 
after drug addition (data not shown). Furthermore, 
the exogenous concentration of BUdR remained 
unchanged for at least 6 hr following drug addition 
at concentrations in excess of 2pM. Hence, the 
relationship between BUdR concentration and 
BrdUTP accumulation was assessed in U251 cells 
during a 2-hr incubation period. When the exogenous 
BUdR concentration ranged from 1 to lOOpM, 
BrdUTP accumulated intracellularly in a linear 
fashion without apparent saturation (data not 
shown). 
Effects of endogenous deoxyribonucleotide pools. 
Since it has been reported that BUdR can result in 
inhibition of CDP reduction by ribonucleotide 
reductase [17], it was of interest to analyze the 
effects of BUdR on the deoxyribonucleoside 
triphosphate pools in the glioblastoma cells. For this 
study, U251 cells were incubated with 2 PM BUdR 
for 25 hr to assess potential time-dependent effects 
on nucleotide pools. Within 2 hr of drug addition, 
BrdUTP had accumulated intracellularly to a value 
of 72 pmol/lO’ cells, a level which was maintained 
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Fig. 1. Effect of BUdR on deoxyribonucleoside 5’- 
triphosphate (dNTP) pools in glioma cells. U251 cells were 
incubated with 2 PM BUdR for 25 hr. Deoxyribonucleotide 
pools were measured periodically by HPLC techniques as 
described in Materials and Methods. Values at 0 hr 
represent control deoxyribonucleotide levels. Key: (0) 
TTP; (0) dCTP; (A) dATP; and (A) dGTP. Results are 
single determinations. 
-. 
0 5 10 15 20 
BUdR Concentration (PM) 
Fig. 2. Decrease in TTP pool level with increasing BUdR 
concentrations. U251 cells were incubated with the 
indicated concentrations of BUdR for 2 hr. TTP levels 
were measured by HPLC techniques as described in 
Materials and Methods. The control ‘ITP value was 
0.329 nmol/lO’ cells. Values represent single deter- 
minations from a typical experiment. 
for at least 12 hr. Figure 1 illustrates the effects of 
this drug exposure on the endogenous deoxy- 
ribonucleoside triphosphate pools. The TTP and 
dCTP pools exhibited the greatest alterations, 
decreasing to 60 and 70% of their initial values, 
respectively. In contrast, the levels of dATP and 
dGTP remained relatively constant during this 
incubation. The decline in the TTP and dCTP values 
was most evident during the first 6 hr after BUdR 
addition, whereas between 6 and 25 hr these values 
decreased only slightly. 
Metabolic effects after removal of BUdR from 
medium. To determine whether or not the observed 
decreases in dCTP and TTP pools were reversible, 
U251 cells were incubated with 20pM BUdR for 
2 hr followed by replacement of the medium with 
fresh drug-free medium. Cells were harvested 
periodically and analyzed for nucleotide content. As 
illustrated in Fig. 3, the levels of the dCTP and TTP 
pools increased following washout of the BUdR, 
attaining the initial untreated control value within 
4 hr. Only minor changes in the dATP and dGTP 
pools were observed during this interval. Thus, the 
changes in the pyrimidine deoxyribonucleotide pools 
induced by BUdR were readily reversible following 
removal of the exogenous BUdR. 
Other similar experiments have demonstrated In the same experiment described in Fig. 3, the 
consistently that exposure of U251 cells to BUdR rate of decay of BrdUTP was assessed. As indicated 
resulted in a decline in TTP and dCTP pools, with in Fig. 4, BrdUTP was eliminated rapidly from the 
little or no effect on the purine deoxyribonucleotide cells following removal of exogenous BUdR. The 
pools. This effect on pyrimidine deoxyribonucleotide rate of BrdUTP elimination was multiexponential, 
pools was exaggerated at higher BUdR concen- with the initial half-life calculated as approximately 
trations, and TTP pools were depressed consistently 15 min. One hour after removal of BUdR, the 
to a greater extent than dCTP pools. Figure 2 BrdUTP half-life increased to more than 2 hr. These 
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Fig. 3. Recovery of TTP and dCTP pools in U251 cells 
after BUdR exposure. Cells were incubated with 10pM 
BUdR for 2 hr followed by replacement of the medium 
with drug-free medium. Deoxyribonucleotide pools were 
measured by HPLC techniques as described in Materials 
and Methods. Key: (0) TIT’; (0) dCTP; (A) dATP; and 
(A) dGTP. Values represent single determinations from a 
typical experiment. 
illustrates the relationship between increasing BUdR 
concentrations and the endogenous ‘lTP levels. 
Exposure to 20yM BUdR for 2 hr reduced TTP to 
approximately 40% of the untreated control value 
(Fig. 2), whereas higher BUdR concentrations (up 
to 100pM) resulted in a decrease in TTP to 
approximately 10% of the control value (data not 
shown). At concentrations of BUdR as high as 
lOOpM, no significant perturbations in dATP or 
dGTP levels were observed (data not shown). 
These studies demonstrate that BrdUTP can 
achieve an intracellular concentration that exceeds 
that of the endogenous deoxyribonucleoside tri- 
phosphates. Indeed, at 100 yM BUdR, BrdUTP can 
achieve a level more than five times higher than the 
TTP value. However, at the clinically achievable 
plasma concentration of 2 ,uM, BrdUTP is typically 
5- to lo-fold lower than the endogenous TTP level. 
BP 43:7-N 
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Table 1. Effect of FUdR on BrdUMP incorporation into 
= 
“, U2Sl DNA 
0 
r. 
0 h % TMP replaced by BrdUMP in DNA = k 01 No FUdR + 10 nM FUdR 2 n 5 1.0 5.70 2 0.04 5.65* 
7.03 f 0.57 6.99 + 0.015 
7.64 * 0.125 8.67 + 0.09 
0 1 2 3 4 Cells were incubated with BUdR alone or in the presence 
of 10 nM FUdR for 6 hr. BrdUMP oration into DNA 
Hours After BUdR Washout was analyzed by a gas chromatography 
Fig. 4. Rate of elimination of BrdUTP in glioma cells. 
assay [lS, 161. Values are means 2 SEM; N = 3 except 
U2Sl cells were incubated with 10 PM BUdR for 2 hr, at 
where indicated. 
which point the medium in each culture was replaced with 
* Single determination. 
drug-free medium. BrdUTP was measured periodically by 
HPLC techniques as described in Materials and Methods. 







Fig. 5. Incorporation of BrdUMP into U2Sl DNA. Glioma 
cells were incubated with 2pM BUdR for 25 hr. The 
amount of BrdUMPincorporated into DNA was determined 
at the indicated intervals as described in Materials and 
Methods. Values are the means 2 SEM of triplicate 
determinations. 
results demonstrate that, in the absence of exogenous 
BUdR, the majority of the intracellular BrdUTP 
(88%) was eliminated within 1 hr. Hence, the 
greatest cellular exposure to BrdUTP occurs during 
the BUdR incubation period. 
Incorporation of BrdUMP into DNA. While the 
incorporation of BrdUMP into DNA has been 
documented in many cell lines, the relationship 
between the metabolism of BUdR and DNA 
incorporation has not been studied. Previous results 
with the U251 cell line demonstrated that BrdUMP 
can replace a maximum of 48% of the thymidylate 
residues in DNA [ll]. We studied the incorporation 
of BrdUMP in cells incubated with 2 ,FLM BUdR for 
25 hr, as illustrated in Fig. 5. Incorporation of 
BrdUMP into cellular DNA increased in an apparent 
linear fashion during the first 12 hr. The data suggest 
that the rate of incorporation decreased at some 
point between 12 and 25 hr. Examination of the 
nucleotide pools during this experiment demon- 
strated that BrdUTP accumulated to a value of 
72 pmol/lO’cells by 2 hr after drug addition and 
remained at approximately that level for the next 
10 hr. However, by 25 hr after drug addition, the 
intracellular BrdUTP concentration had decreased 
to 18 pmol/lO’cells. Analysis of the amount of 
BUdR remaining in the medium during the course 
of the experiment indicated that the drug remained 
at a constant level for at least the first 6 hr, but by 
24 hr it had decreased to 0.18 PM. These data suggest 
that, in the presence of a constant exogenous BUdR 
concentration, U251 cells maintain a constant 
BrdUTP level which is associated with a continual 
increase of BrdUMP incorporation into DNA. 
However, degradation of the exogenous BUdR 
results in a decrease in the cellular BrdUTP 
concentration and a slower rate of incorporation of 
the analog into DNA. 
Attempts to increase the DNA incorporation of 
BrdUMP have centered around adding agents which 
decrease endogenous TTP pools such as FUdR or 
FUra [2,3,11,18]. However, Mancini et al. [ll] 
have reported recently that the incorporation of 
BrdUMP into U251 cellular DNA during a 24-hr 
incubation with BUdR was not augmented by 
simultaneous exposure to FUdR. In an effort to 
elucidate the mechanism responsible for this lack of 
modulation by FUdR, we examined the effect of 
FUdR on the cellular levels of BrdUTP and TTP 
and, in the same cell population, measured the 
incorporation of BrdUMP into cellular DNA. We 
employed a 6-hr incubation period for these studies 
to expose the cells to a constant level of BUdR. 
Table 1 illustrates that, over a 6-hr time period, 
10nM FUdR did not increase substantially the 
incorporation of BrdUMP into the DNA of U251 
glioblastoma cells, in accord with previous results 
employing longer incubation periods [ll]. Table 2 
demonstrates that FUdR did not decrease the cellular 
‘ITP pool level in these cells, nor did it affect the 
amount of BrdUTP that accumulated in these cells. 
Other experiments have demonstrated consistently 
that a 6-hr incubation of U251 cells with 10 nM 
FUdR does not depress ‘ITP pools (data not shown). 
Thus, since the levels of ‘ITP and BrdUTP were not 
altered by FUdR, this analog should have no effect 
on the incorporation of BrdUMP into DNA. It will 
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Table 2. Effect of FUdR on TTP and BrdUTP pools 
W’JI WdRl y BrdUTP 
(nM) (nmol/lO cells) (nmol/lO’ cells) 
0 0 0.316 
1.0 0 0.212 0.011 
2.5 0 0.240 0.038 
5.0 0 0.224 0.052 
0 10 0.286* 
1.0 10 0.274 0.011 
2.5 10 0.200 0.016 
5.0 10 0.218 0.044 
U251 cells were incubated with BUdR alone or in the 
presence of 10nM FUdR for 6 hr. Nucleotide pool 
measurements were performed as described in Materials and 
Methods. Values are averages of duplicate determinations, 
except where indicated. 
* Single determination. 
be important to determine whether longer incubation 
periods or higher concentrations of FUdR are able 
to depress TTP pools in these cells and, if not, the 
mechanism by which U251 cells are insensitive to 
the nucleotide effects of FUdR must be elucidated. 
DISCUSSION 
While the exact mechanisms by which BUdR 
exerts its biologic effects are not known, it appears 
that several of these effects are due, in part, to its 
incorporation into cellular DNA [l, 21. Although 
this incorporation is dependent upon the intracellular 
conversion of BUdR to BrdUTP, there are few 
reports describing the rate and extent of accumulation 
of this important metabolite. Despite current interest 
in BUdR as adjunct therapy in patients with brain 
tumors, the data on the metabolism of BUdR in 
gliomas are sparse. Thus, we have investigated the 
metabolism of BUdR in a cultured glioblastoma cell 
line as a first step in the elucidation of the relevant 
biochemical parameters which determine the level 
of BrdUMP incorporation into DNA. 
Thymidine kinase is the first enzyme in the 
metabolic pathway that converts BUdR to BrdUTP. 
BUdR is reported to be a good substrate for this 
enzyme, with projected K,,, values in the range of 2 
to 3pM, similar to the Km value for the native 
substrate thymidine [19-211. In the data presented 
here, BrdUTP rapidly accumulated to a steady-state 
level, which may reflect a high affinity of thymidine 
kinase in the U251 cells for BUdR. These data also 
demonstrated that BrdUTP accumulation was not 
saturated at concentrations of BUdR as much as 50- 
fold above its putative K,,, value for thymidine 
kinase. This finding may be explained by the 
observation that the endogenous TTP level decreased 
substantially in response to BUdR exposure. Since 
TTP can act as a feedback inhibitor on thymidine 
kinase [22-241, it is possible that reduction in the 
TTP level allows the U251 cells to phosphorylate 
BUdR faster by relieving the innate inhibition of 
the enzyme. Other researchers have demonstrated 
that BrdUTP can act as a feedback inhibitor of 
partially purified mammalian thymidine kinase [ 191. 
Thus, it may have been expected that accumulation 
of high levels of BrdUTP would inhibit its further 
phosphorylation. However, our data indicate that 
BrdUTP at levels up to 544 pmol/lO’ cells does not 
inhibit the phosphorylation of BUdR in the U251 
line. It is likely that the interaction between the 
decreasing TTP levels and perhaps the presence of 
other cellular nucleotides prevent BrdUTP from 
significantly inhibiting thymidine kinase activity in 
the intact glioblastoma cells. 
The results in Fig. 1 illustrate that exposure to 
BUdR results in a significant decrease in both the 
endogenous dCTP and ‘ITP pool levels. Other 
investigators have also demonstrated that the cellular 
dCTP pools decrease during exposure to BUdR, 
apparently due to feedback inhibition of ribo- 
nucleotide reductase by BrdUTP [17,25]. BrdUTP 
may be acting in a manner similar to dUTP which, 
according to the current models of regulation of 
ribonucleotide reductase, results in decreased 
production of both dCTP and TTP [26,27]. Indeed, 
adding deoxyuridine to lymphoid cells in culture can 
produce reductions in dCTP pools [28]. The 
observation that TTP pool levels were decreased to 
a greater extent than dCTP levels may be explained 
by the fact that decreases in TTP may also be 
effected through inhibition of thymidine kinase 
activity, as described in the preceding paragraph. In 
addition, cellular accumulation of BrdUMP may 
result in inhibition of thymidylate synthetase activity, 
as reported for bacterial sources of this enzyme 
[29,30]. Thus. there are potentially three mechanisms 
by which TTP pool levels can be decreased in 
glioblastoma cells, whereas dCTP pools appear to 
be decreased through only one mechanism. 
To our knowledge, there has been only one 
previous report describing a reduction in the cellular 
TTP pool in response to BUdR [31]. Using Friend 
leukemia cells, it was demonstrated that 4 PM BUdR 
(in the presence of 1 mM butyric acid) reduced the 
TTP pools to approximately 50% of control within 
30min and sustained that reduced nucleotide level 
for at least 6 hr. The results presented here illustrate 
that this reduction in TTP occurs with BUdR 
treatment in the U251 glioblastoma cells (in the 
absence of other additives). In addition, the data in 
Figs. 2 and 3 extend the previous results by 
demonstrating that the reduction in the TTP pool 
was dependent upon the BUdR concentration and, 
furthermore, that this effect was readily reversible 
upon washout of BUdR. In contrast to the results 
presented here, the data from the Friend leukemia 
cells demonstrated that there was little, if any, 
change in the dCTP pool in response to BUdR, 
while a 2-fold increase in dATP was noted. Thus, 
these data indicate that nucleotide pool changes 
mediated by BUdR are cell line specific and 
emphasize the necessity to define these alterations 
for each cell line under study. 
Although the reduction in TTP level in response 
to BUdR has important implications for the 
antitumor and radiosensitizing properties of the 
thymidine analog (as discussed below), little 
information exists on this effect, which may be 
explained by a couple of observations. First, many 
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investigators employ the DNA polymerase assay to 
measure the levels of cellular deoxyribonucleotides, 
and it has been shown that this assay cannot 
distinguish between BrdUTP and TTP [32]. Thus, 
TTP levels were not measured in many studies of 
BUdR effects on nucleotide pools. Second, it was 
recognized more than 30 years ago that BrdUMP 
incorporation into DNA could be enhanced by 
decreasing the endogenous level of the competing 
TTP pool [3]. Thus, many studies examining the 
biologic effects of BUdR also employ inhibitors of 
TTP synthesis, such as FUdR. In such studies, 
depression of TTP pools is expected and attributed 
to the effects of the inhibitor of TTP synthesis. The 
data presented in this paper demonstrate that, in 
addition to the depression of cellular dCTP pools, 
BUdR induces an even more prominent reduction 
in the endogenous TTP level. This effect should be 
taken into consideration when adding BUdR and 
FUdR in combination since, at high levels of BUdR, 
the reduction in TTP pools may not be enhanced by 
FUdR. Indeed, Mancini et al. [ll] demonstrated 
that, in the D-54 glioblastoma cell line, BrdUMP 
incorporation into DNA could be enhanced by 
FUdR at concentrations of BUdR less than 10 PM, 
but at higher BUdR concentrations this effect was 
abolished. Experiments are underway to determine 
whether FUdR reduced the TTP pool levels at low 
but not high BUdR concentrations. 
The BUdR-induced decrease in TTP pools has a 
dual beneficial effect on the incorporation of 
BrdUMP into DNA. As discussed above, depression 
of the endogenous TTP pool may increase the 
phosphorylation of BUdR, thus increasing the 
amount of precursor available for DNA incor- 
poration. Furthermore, a reduction in cellular ‘ITP 
decreases the concentration of the natural competitor 
of BrdUTP for the replicative DNA polymerases 
which should enhance the incorporation of BrdUMP 
into DNA. Considering that the reduction in ‘ITP 
pools became more profound as the BUdR 
concentration was increased, it may be possible to 
administer BUdR at a concentration that would 
suppress the TTP pool to an undetectable level. 
However, at least 10% of the control level of TI’P 
remained in the cell in the presence of 100 PM 
BUdR, a highly cytotoxic concentration that is 
impractical to achieve clinically [l, 2, 8, 111. Thus, 
it would be most desirable to employ a second agent 
to effect an efficient decrease in endogenous TTP 
pools with the goal of enhancing BrdUMP 
incorporation into DNA at less toxic BUdR con- 
centrations. The thymidylate synthetase inhibitor 
FUdR is a logical choice of agents to use since it can 
decrease cellular TTP pools at concentrations which 
do not appear to be toxic [30,33]. However, data 
presented in this paper demonstrated that 10nM 
FUdR was unable to effect a decrease in the 
endogenous TTP pools in the U251 cell line either 
by itself or in the presence of BUdR. Consequently, 
BrdUMP incorporation into cellular DNA was not 
enhanced by the simultaneous administration of 
FUdR. A previous report indicated that con- 
centrations of FUdR up to 25 nM were unable to 
enhance BrdUMP incorporation into U251 cell DNA 
[ll]. The failure of 10 nM FUdR to decrease TTP 
pools is most likely due to a lack of inhibition of 
thymidylate synthetase, for which there may be 
several explanations. FUdR requires phos- 
phorylation to its 5’-monophosphate, FdUMP, which 
must then combine with thymidylate synthetase and 
a reduced folate cofactor in order to inhibit the 
enzyme [30,33]. Hence, inadequate accumulation 
of FdUMP (possibly due to high cellular thymidine 
levels) or too little endogenous folate could prevent 
formation of the inhibitory complex. Alternatively, 
these cells may possess high levels of thymidylate 
synthetase or an altered form of the enzyme which 
is insensitive to inhibition by FdUMP. These 
hypotheses are presently under investigation. 
While incorporation of BrdUMP into cellular 
DNA appears to be necessary for the antitumor and 
radiation sensitizing effects of BUdR, it is not known 
whether the overall level of incorporation of 
BrdUMP or perhaps its misincorporation for a 
nucleotide other than thymidylate results in its 
biologic effects. These two types of incorporation 
have been considered in detail in studies of the 
mutagenic activity of BUdR [25,34-361. Although 
some investigators believe that mutagenesis is 
proportional to the total amount of BrdUMP 
incorporated into DNA [34], other data indicate that 
the less frequently occurring substitution of BrdUMP 
for dCMP is the critical mutagenic event [25,35]. If 
the antitumor and/or radiosensitizing effects are due 
to the overall level of BrdUMP incorporation into 
DNA, then reducing the cellular concentration of 
TTP will be crucial for enhancing BrdUMP 
incorporation. However, if misincorporation of 
BrdUMP for dCMP is critical for its biologic effects, 
then it will be more important to reduce the 
endogenous dCTP pools to increase the likelihood 
that this type of misincorporation will occur. Hence 
it is necessary to distinguish which of these 
biochemical events is responsible for the antitumor 
and radiosensitizing effects of BUdR so that this 
information can be exploited in designing optimal 
chemotherapeutic protocols for this agent. 
Acknowledgement-This work was supported in part by 
NIH Grant POlCA42761 from the National Cancer 
Institute. 
REFERENCES 
Prusoff WH and Goz B, Halogenated pyrimidine 
deoxyribonucleosides. In: Handbook of Experimental 
Pharmacoloav (Eds. Sartorelli AC and Johns DG). 
Vol. 38, Paz 2, pp. 272-347. Springer, New York: 
1975. 
Goz B, The effects of incorporation of 5-halogenated 
deoxyuridines into the DNA of eukaryotic cells. 
Pharmacol Rev 29: 249-272, 1978. 
Djordjevic B and Szybalski W, Genetics of human 
cell lines: III. Incorporation of 5-bromo- and 5- 
iododeoxyuridine into the deoxyribonucleic acid of 
human cells and its effect on radiation sensitivity. J 
Exp Med 112: 509-531, 1960. 
Szybalski W, X-ray sensitization by halopyrimidines. 
Cancer Chemother Rep 58: 539-557, 1974. 
5. Hoshino T, Radiosensitization of brain tumors. In: 
Modern Radiotherapy and Oncology-Central Nervous 
System Tumors (Ed. Deely TJ), pp. 170-183. 
Butterworths, London, 1974. 
Metabolic effects of BUdR 1585 
6. Kinsella TJ, Mitchell JB, Russo A, Aiken M, Morstyn 
G, Hsu SM, Rowland J and Glatstein E, Continuous 
intravenous infusions of bromodeoxyuridine as a 
clinical radiosensitizer. J Clin Oncol 10: 1144-1150, 
1984. 
7. Phillips TW, Chandler WF, Kindt GW, Ensminger 
WD. Greenbere HS. Seeeer JF. Doan KM and Gvves 
JW,‘New impl&ttable co%inuous administration-and 
bolus dose intracarotid drug delivery system for the 
treatment of malignant gliomas. Neurosurgery 11: 213- 
218, 1982. 
Hegarty TJ, Thornton AF, Diaz RF, Chandler WF, 
Ensminger WD, Junck L, Page MA, Gebarski SS, 
Hood TW, Stetson PL, Tankanow RM, McKeever 
PE, Lichter AS and Greenberg HS, Intra-arterial 
bromodeoxyuridine radiosensitization of malignant 








Stetson PL, Shukla UA, Amin PR and Ensminger 
WD , High performance liquid chromatographic method 
for the determination of bromodeoxyuridine and its 
major metabolite, bromouracil, in biological fluids. J 
Chromatogr 341: 217-222, 1985. 
Kinsella TJ, Mitchell JB, Russo A, Morstyn G and 
Glatstein E, The use of halogenated thymidine analogs 
as clinical radiosensitizers: Rationale, current status, 
and future prospects: non-hypoxic cell sensitizers. Znt 
J Radiat Oncol Biol Phys 10: 1399-1406, 1984. 
Mancini WR, Stetson PL, Lawrence TS, Wagner JG, 
Greenberg HS and Ensminger WD, Variability of 5- 
bromo-2’-deoxyuridine incorporation into DNA of 
human glioma cell lines and modulation with 
fluoropyrimidines. Cancer Res 51: 870-874, 1991. 
Kit S, Dubbs DR, Piekarski LJ and Hsu TC, Deletion 
of thymidine kinase activity from L cells resistant to 
bromodeoxyuridine. Exp Cell Res 31: 297-312, 1963. 
Ellero J, Ensminger WD and Shewach DS, Metabolism 
of BUdR in a human glioblastoma cell line. Proc Am 
Assoc Cancer Res 32: 416, 1991. 
14. Bigner DD, Bigner SH, Pontent J, Westermark B, 
Mahaley MS Jr, Ruoslahti H, Herschman H, Eng LF 
and Wikstrand CJ, Heterogeneity of genotypic and 
phenotypic characteristics of fifteen permanent cell 
lines derived from human gliomas. J Neuropathol Exp 
Neural 40: 201-229, 1981. 
15. Maybaum J, Kott MG, Johnson NJ, Ensminger WD 
and Stetson PL, Analysis of bromodeoxyuridine 
incorporation into DNA: Comparison of gas 
chromatographic/mass spectrometric, CsCl gradient 
sedimentation, and specific radioactivity methods. Anal 
Biochem 161: 164-171, 1987. 
16. Stetson PL, Maybaum J, Shukla UA and Ensminger 
WD, Simultaneous determination of thymine and 
bromouracil in DNA hydrolysates using gas chroma- 
tography-mass spectrometry with selected-ion moni- 
toring. J Chromatogr 375: 1-9, 1986. 
17. Meuth M and Green H, Induction of a deoxycytidineless 
state in cultured mammalian cells by bromo- 
deoxyuridine. Cell 2: 109-112, 1974. 
18. Kaufman ER and Davidson RL, Bromodeoxyuridine 
mutagenesis in mammalian cells: Mutagenesis is 
independent of the amount of bromouracil in DNA. 
Pro; Nat1 Acad Sci USA 15: 4982-4986, 1978. 
19. Lee L-S and Cheng Y-c, Human deoxythymidine kinase 
II: Substrate specificity and kinetic behavior of the 
cytoplasmic and mitochondrial isozymes derived from 
blast cells of acute myelocytic leukemia. Biochemistry 
15: 3686-3690, 1976. 
20. Bresnick E and Thompson UB, Properties of 
deoxythymidine kinase partially purified from animal 
tumors. J Biol Chem 240: 3967-3974, 1965. 
21. Kizer DE and Holman L, Purification and properties 
of thymidine kinase from regenerating -rat- liver. 
Biochim Biophvs Acta 350: 193-200, 1973. 
22. Ives DH, Morse PA Jr and Potter VR, Feedback 
inhibition of thymidine kinase by thymidine triphos- 
ohate. J Biol Chem 238: 1467-1474. 1963. 
23. Prusoff WH and Chang PK, Regulation of thymidine 
kinase activity by 5-iodo-2’-deoxyuridine 5’-tri- 
phosphate andbeoxythymidine 5’-tripttosphate. Chem 
Biol Interact 1: 285-299. 1969/1970. 
24. Fischer PH and Baxter’ D, Enzyme regulatory site- 
directed drugs: Modulation of thymidine triphosphate 
inhibition of thymidine kinase by 5’-amino-5’-deoxy- 
thymidine. Mol Pharmacol22: 231-234, 1982. 
25. Ashman CR and Davidson RL, Bromodeoxvuridine 
mutagenesis in mammalian cells is related to 
deoxvribonucleotide ~001 imbalance. Mol Cell Biol 1: 
254-&O, 1981. ’ 
26. Moore EC and Hurlbert RB, Regulation of mammalian 
deoxyribonucleotide biosyntheiis by nucleotides as 
activators and inhibitors. J Biol Chem 241: 4802-4809. 
1966. 
27. Thelander L and Reichard P, Reduction of ribo- 
nucleotides. Annu Rev Biochem 48: 133-158, 1979. 
28. Perez DJ and Tattersall MHN, The metabolic basis of 
deoxyuridine cytotoxicity: Studies of cultured human 
lymphoblasts. Mol Pharmacol22: 166174, 1982. 
29. Flaks JG and Cohen SS, Virus-induced acquisition of 
metabolic function. III. Formation and some properties 
of thymidylate synthetase of bacteriophage-infected 
Escherichia coli. J Biol Chem 234: 2981-2986, 1959. 
30. Watava Y. Santi DV and Hansch C. Inhibition of 
31. 
LactdbacilZus casei thymidylate synthetase by 5- 
substituted 2’-deoxyuridylates. Preliminary quan- 
titative structure-activity relationship. J Med Chem 20: 
14691473, 1977. 
Bick MD, Bromodeoxyuridine inhibition of Friend 
leukemia cell induction. Mechanism of reversal by 







Bick MF, A quantitative method for distinguishing 
BrdUTP and dTTP in soluble pools. Anal Biochem 78: 
582-585, 1977. 
Heidelberger C, Fluorinated pyrimidines and their 
nucleosides. In: Handbook of Experimental Phar- 
macology (Eds. Sartorelli AC and Johns DG), Vol. 
38, Part 2, pp. 193-231. Springer, New York, 1975. 
Hopkins RL and Goodman MF, Deoxyribonucleotide 
pools, base pairing, and sequence configuration 
affecting bromodeoxyuridine- and 2-aminopurine- 
induced mutagenesis. Proc Nat1 Acad Sci USA 77: 
1801-1805, 1980. 
Davidson RL, Broeker P and Ashman CR, DNA 
base sequence changes and sequence specificity of 
bromodeoxyuridine-induced mutations in mammalian 
cells. Proc Nat1 Acad Sci USA 85: 4406-4410, 1988. 
Sargent RG, Ji J, Mun B and Mathews CK, 
Ribonucleotide reductase: A determinant of 5- 
bromodeoxyuridine mutagenesis in phage T4. Mol Gen 
Genet 217: 13-19, 1989. 
